SkinBioTherapeutics (LON:SBTX) Shares Down 34.6% – What’s Next?

Shares of SkinBioTherapeutics plc (LON:SBTX) dropped 34.6% on Friday . The stock traded as low as GBX 6.25 and last traded at GBX 6.28. Approximately 360,278 shares were traded during trading, a decline of 93% from the average daily volume of 4,816,163 shares. The stock had previously closed at GBX 9.60.

SkinBioTherapeutics Stock Down 18.8%

The business’s 50 day moving average is GBX 14.36 and its 200-day moving average is GBX 15.05. The stock has a market cap of £20.22 million, a price-to-earnings ratio of -25.16 and a beta of 0.47. The company has a debt-to-equity ratio of 10.55, a quick ratio of 10.01 and a current ratio of 4.84.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.